Stéphane Bancel, Moderna CEO (AP Images, Boston Herald)

Mod­er­na says its mR­NA flu vac­cine cleared ear­ly stud­ies, but com­par­isons with oth­er vac­cines dri­ve stock down

Mod­er­na says that it’s on its way to hav­ing an mR­NA vac­cine against not one, but two dif­fer­ent sea­son­al virus­es.

The biotech re­leased the first ear­ly da­ta from its flu pro­gram Fri­day morn­ing, an­nounc­ing that all dos­es of the shot sig­nif­i­cant­ly boost­ed an­ti­bod­ies in younger and old­er adults with­out “sig­nif­i­cant safe­ty find­ings.”

A 500-per­son Phase II will con­firm dose lev­els and com­pare it to an ap­proved flu vac­cine, the com­pa­ny said, and prepa­ra­tions for a large piv­otal tri­al are un­der­way. Mod­er­na said it is al­so ad­vanc­ing new de­signs that can have po­ten­tial­ly broad­er cov­er­age of dif­fer­ent flu strains than cur­rent shots.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.